Chair's Address to Shareholders
Released
Released
Announcement PDF
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
ASX Announcement 5 November 2026
2026 Annual General Meeting – Chairman’s Address to
Shareholders
In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (Atomo) attaches
the Chairman’s Address to be delivered at Atomo’s 2026 Annual General Meeting.
For more information, please contact For Media questions, please contact:
Cheri Walker, PhD George Hazim
Atomo Diagnostics Director
cheri.walker@atomodiagnostics.com Media and Public Affairs Australia
Phone: +61 2 9099 4750 georgehazim@mediaaffairs.com.au
Phone: +61 417 516 262
This announcement was authorised by the Managing Director & CEO on behalf of the Board
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
Chairman’s Address to Shareholders — Atomo Diagnostics Limited (ASX: AT1)
5th
November 2026
Good morning, everyone, and welcome to Atomo Diagnostics’ Annual General Meeting. On
behalf of the Board, I thank you for joining us today and for your continued support of the
Company.
The past year has been a transitional year for Atomo. Whilst navigating a volatile operating
environment across the global diagnostics sector, we have continued to execute our strategy
of delivering innovative, user-centred rapid testing solutions that improve access to accurate
and reliable diagnostics worldwide.
Atomo is starting to fulfil on the promise from its current proprietary HIV franchise and through
OEM partnerships, posting significant year-on-year growth of more than 40%. As the
company prepares for future global endeavours, Atomo transitioned its Chief Executive role
to Dr. Cheri Walker, to focus on commercial sales, partnerships and the new product pipeline.
We thank John Kelly, the founding CEO for his long service that has brought Atomo to this
exciting juncture.
Our focus remains on the patient, providing blood-based testing products that bring increased
usability and performance to the patient setting, in both professional use and the self-test
setting.
The shift to decentralised, at-point-of-care and self-testing solutions remains a strong and
growing trend. Government policy and regulators are continuing to see the benefits of point-
of-care and self-testing. As new and better tests remove the need for confirmation testing,
treatment decisions can be made more rapidly in locations where there is little access to
centralised testing or the time for that testing could delay life-saving care.
Atomo’s core purpose remains clear — to simplify and democratise diagnostic testing through
our patented device technology. Our products are designed to make testing easier, safer, and
more reliable, whether used by healthcare professionals or self-test users in the home.
Over the past year, we have:
• Advanced Atomo’s Active Syphilis product and added ALT liver and Gen 4 HIV to our
proprietary product pipeline;
• Completed development projects with two OEM providers for Ferritin and Brain
Disease/Stroke indications;
• Continued to grow our HIV franchise by more than 40% through international, public
health and pharmacy sales;
• Made strategic moves to commission a second blister machine in Sydney and started
developing new tooling to add more flexibility plus began the development of higher
cavitation moulding meant to improve gross margins; and
• Streamlined our operating model to enhance efficiency and preserve capital.
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
Atomo HIV franchise continues to grow and perform well, providing solid growth of 21% in
FY26. Atomo’s technology is proven, being the first HIV/AIDS self-test to be approved by the
Australian Therapeutic Goods Administration (TGA). We continue to drive growth in
international markets, pharmacies, and public health applications across ANZ.
Our OEM franchise is starting to drive accelerated growth for Atomo, posting more than 200%
year-on-year growth. Atomo is the exclusive licensor, manufacturer and supplier of the Pascal
cassette to Lumos (ASX:LDX) for its FebriDx® product. Using Atomo’s Pascal cassette,
FebriDx® has previously secured 510k clearance from the US FDA and received CLIA waiver
from the US FDA. The CLIA waiver trial showed that Pascal has enabled greater than 99%
concordance between trained and untrained operators using FebriDx®.
The Board remains confident that the Company’s technology platform, intellectual property,
and strong global relationships position Atomo well to participate in the continuing evolution of
decentralised diagnostics.
During the year we undertook a successful capital raising, supporting working capital and
enabling us to reshape our organisation and position ourselves for the next growth phase. We
want to thank existing and new shareholders for their support.
In parallel, management has taken decisive steps to reduce costs and strengthen our balance
sheet. This financial discipline will support our ability to pursue commercial opportunities in a
sustainable manner while continuing to invest selectively in innovation.
Looking forward, Atomo’s strategy is centred on several priorities including:
1. Expanding Atomo’s own proprietary test pipeline (as exampled by active syphilis, ALT
Liver and recently announced HIV Gen 4);
2. Leveraging our proven platform and identifying new OEM partnerships in testing
applications where usability and accuracy are critical; and
3. Maintaining operational excellence, focus on improving operating scale and gross
margins, and prudent capital management as we build towards profitability.
I would like to take this opportunity to thank my fellow Director, Mr Tony May, for his support
and guidance. Also, our CEO/MD, Dr Cheri Walker, and the entire Atomo team for their
dedication and professionalism throughout the year. Their efforts have ensured that Atomo
continues to be recognised as a leader in user-centric diagnostic design and manufacturing.
I would also like to acknowledge the ongoing support of our shareholders. Your confidence in
our vision enables us to continue driving innovation in an industry that plays such a vital role
in global public health.
The Board remains committed to delivering long-term value through disciplined execution,
strategic partnerships, and continued focus on innovation and quality.
Thank you once again for your attendance and support. I will now hand over to our CEO/MD,
Dr Cheri Walker, to provide further detail on the Company’s operational and commercial
progress during the year.
Share your feedback
Discover